{
    "clinical_study": {
        "@rank": "8422", 
        "arm_group": {
            "arm_group_label": "Nivolumab (BMS-936558)", 
            "arm_group_type": "Experimental", 
            "description": "Nivolumab (BMS-936558) Intravenous solution   every 2 weeks"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the rate and frequency of high-grade (CTCAE v4.0\n      Grade 3 or higher), treatment-related, select adverse events in subjects with histologically\n      confirmed stage III (unresectable) or stage IV melanoma and progression post prior treatment\n      containing an anti-Cytotoxic T Lymphocyte Antigen (CTLA-4) monoclonal antibody, treated with\n      Nivolumab (BMS-936558) at a dose of 3 mg/kg every two weeks."
        }, 
        "brief_title": "A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)", 
        "completion_date": {
            "#text": "October 2020", 
            "@type": "Anticipated"
        }, 
        "condition": "Melanoma", 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "For more information regarding BMS clinical trial participation, please visit\n        www.BMSStudyConnect.com\n\n        Inclusion Criteria:\n\n          -  Subjects with histologically confirmed malignant melanoma\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS):\n\n               -  PS 0 to 1\n\n               -  PS 2\n\n          -  Previously treated unresectable stage III or stage IV melanoma as per the American\n             Joint Committee on Cancer 2010 Guidelines regardless of BRAF mutation status\n\n          -  Subjects must have experienced evaluable Response Evaluation Criteria In Solid Tumors\n             (RECIST 1.1)-defined disease progression\n\n          -  Prior treatment with chemotherapy, interferon (adjuvant setting), Interleukin (IL-2),\n             BRAF/MEK inhibitors for subjects with known BRAF mutations, Mitogen-activated or\n             extracellular signal- regulated protein kinase (MEK) inhibitors for Neuroblastoma Ras\n             Viral (v-ras) oncogene homolog (NRAS) mutations, and cKIT inhibitor subjects with\n             known cKIT mutations are allowed\n\n        Exclusion Criteria:\n\n          -  Leptomeningeal metastases are excluded\n\n          -  Subjects with untreated, active Central Nervous System (CNS) metastases are excluded"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1800", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 29, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02156804", 
            "org_study_id": "CA209-172", 
            "secondary_id": "2014-001286-28"
        }, 
        "intervention": {
            "arm_group_label": "Nivolumab (BMS-936558)", 
            "intervention_name": "Nivolumab (BMS-936558)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Antibodies, Monoclonal"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 2, 2014", 
        "number_of_arms": "1", 
        "official_title": "A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody", 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "European Union: European Medicines Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Rate and frequency for high-grade (CTCAE v4.0 Grade 3 or higher) treatment-related, select adverse events in subjects with melanoma", 
                "safety_issue": "Yes", 
                "time_frame": "Safety assessments for approximately 2 years"
            }, 
            {
                "measure": "Rate and frequency of AEs regardless of causality", 
                "safety_issue": "Yes", 
                "time_frame": "Safety assessments for approximately 2 years"
            }, 
            {
                "measure": "Rate and frequency of treatment-related AEs", 
                "safety_issue": "Yes", 
                "time_frame": "Safety assessments for approximately 2 years"
            }, 
            {
                "measure": "Rate and frequency of any AEs of special interest (AEOSI), such as pulmonary, gastrointestinal, cuteaneous, renal, hepatic, pancreatic, endocrine, infusion-related, or hypersensitivity", 
                "safety_issue": "Yes", 
                "time_frame": "Safety assessments for approximately 2 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02156804"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Outcome (grade of resolution; duration of Adverse Event (AE)-specific treatment) of all high-grade (CTCAE v4.0 Grade 3 or higher) treatment-related adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "approximately 3 years"
            }, 
            {
                "measure": "Time to overall survival (OS) and survival at Years 1 and 2 after treatment and beyond", 
                "safety_issue": "No", 
                "time_frame": "Survival status every couple of  weeks for approximately 8 years,  until death, lost to follow-up, or withdrawal of study consent"
            }, 
            {
                "measure": "Investigator-assessed best overall response (BOR)", 
                "safety_issue": "No", 
                "time_frame": "approximately 3 years"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}